Good morning, and welcome to Shoe Carnival's First Quarter Earnings Conference Call. Today's conference call is being recorded, and is also being broadcast via webcast. Any reproduction or rebroadcast ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Russian subsidiary is getting close to filing for bankruptcy, Reuters reported. Microsoft Rus LLC is getting close to filing, according t ...

The Silver/Gold ratio is among nuts and bolts of our work that keeps us on right track through all macro phases. Click here ...

FY2026 beats expectations despite China's $4.5B hit. Click for why NVDA valuation remains attractive with rising consensus ...

Reinsurance Group Of America receives a buy rating as a top reinsurance firm. Read more about RGA's growth potential, global ...

Argan capitalizes on energy transition trends with a $1.4B order book, no debt, and robust growth prospects. Learn more about ...

GSL's asset-light model, strong backlog, and robust Q1 results support our strong buy rating and target price increase to $33 ...

J. M. Smucker's fundamentals remain steady. Technically, shares are range-bound and lack momentum. Click here to read why I ...

Mongeau signaled that roughly 80% of targeted annual operating expense savings of at least $20 million have already been identified, with over 50% executed. An early prepayment of $100 million U.S.

Edwards Lifesciences is projected to deliver steady profit and revenue growth through 2026. Click here to read more on EW ...

Nuclear energy holds long-term potential, but stocks like Centrus Energy may be overvalued. Read the latest stock analysis ...